The results of a chelation study using Ca-/Zn-DTPA to treat 25 patients diagnosed with Gadolinium Deposition Disease (GDD) will be published in the June 2018 issue of Investigative Radiology. The complete article is not freely available to the public. However, you can find the abstract of, “Intravenous Calcium-/Zinc-Diethylene Triamine Penta-Acetic Acid in Patients with Presumed Gadolinium Deposition Disease – A Preliminary Report on 25 Patients”, by Semelka et al. at https://www.ncbi.nlm.nih.gov/pubmed/29419708
According to the FDA, Calcium-DTPA (Ca-DTPA) and Zinc-DTPA (Zn-DTPA) are drug products that have been used for over 40 years to speed up excretion of the actinide elements plutonium, americium, and curium from the body. Gadolinium (Gd) is a lanthanide series element that shares a number of chemical properties with actinides. The purpose of the study was to determine if the FDA-approved actinide metal decorporation agents Ca-/Zn-DTPA could be beneficial for symptomatic patients with GDD who had retained gadolinium from the gadolinium-based contrast agents (GBCAs) that had been administered for their MRIs. (more…)
(A PDF of this Viewpoint is available for download.)
This is a re-written version of some emails that I have sent on the subject, so please read it with that in mind. They were addressed to several people in the MRI-Gadolinium Toxicity Support Group.
A word before you read this. I usually do not post this kind of thinking on the support group because many people hold out chelation as their only hope. I do not want to squelch their hope and I do not just want to be negative on it. As you will see below, I have tried it and decided that it is not for me. So I just tell my story. Everyone has to make their own decisions.
Let me provide some background. My last contrast MRI (of 8 in total) was in October 2009 when I had three contrast MRIs within a two-week period. (more…)